The strong anti-tumor activity of monotherapy with F8-IL2, together with the lack of synergistic effect when F8-IL2 was administered with T cells, indicated that the immunocytokine preferentially acted on T cells present in the tumor prior to adoptive cell transfer. Here, IL2 is linked to neoplasm.